A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg Once-Daily (QD) and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD)
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00002444/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD).
提供机构：
Vivli
创建时间：
2018-10-27
